Efficacy analysis of von Willebrand factor in human coagulation factor FⅧ concentrates in China
10.13303/j.cjbt.issn.1004-549x.2021.06.002
- VernacularTitle:我国人凝血因子Ⅷ制品中血管性血友病因子效力分析
- Author:
Xi DU
1
;
Li MA
1
;
Zongkui WANG
1
;
Shengliang YE
1
;
Fengjuan LIU
1
;
Rong ZHANG
1
;
Na SU
1
;
Fangzhao LIN
1
;
Haijun CAO
1
;
Changqing LI
1
Author Information
1. Institute of Blood Transfusion, Chinese Academy of Medical Sciences & Chinese Academy of Medical Sciences, Chengdu 610052, China
- Publication Type:Journal Article
- Keywords:
von Willebrand Factor;
human coagulation factor FⅧ concentrates;
von Willebrand disease;
vWF multimers
- From:
Chinese Journal of Blood Transfusion
2021;34(6):574-578
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To obtain the quality information of von Willebrand factor (vWF) in coagulation factor Ⅷ (FⅧ) concentrates in China. 【Methods】 FⅧ concentrates produced by 7 domestic blood product manufactures and 1 foreign manufacture were collected, then FⅧ and vWF contained in FⅧ concentrates were evaluated. 【Results】 The activity loss of vWF was more than 25% in 2 of the 7 domestic FⅧ concentrates. The ratio of vWF activity to FⅧ activity in FⅧ concentrates from different domestic manufactures was significantly different (P<0.05). The ratio in FⅧ concentrates prepared by C, D, F manufacturer was greater than 1, which was similar to that in willate@ approved abroad for the treatment of vWD. The ratio in FⅧ concentrates prepared by E manufacturer was greater than 0.7 and less than 1, and by A, B, G manufacturers was less than 0.5. In addition, the specific activities of FⅧ and vWF were significantly different among different FⅧ concentrates in China (P<0.05), and the specific activities of FⅧ and vWF were much lower than that of willate@. 【Conclusion】 The variation of vWF quality between domestic FⅧ concentrates and willate@ is mainly due to the different in vWF content. After the comprehensive consideration of various indicators, the FⅧ concentrates made by C and D manufacturers may be used in the treatment of vWD.
